Health Economics›Cholangiocarcinoma›Metastatic disease, all lines of therapy

Metastatic disease, all lines of therapy

Cholangiocarcinoma · 16 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~16.5 mo	~13.9 mo	~2	~R 573 911 PFS proxy · indirect	7
GEMOX-B Variant #01	—	R 44 038	28d	—	—	~2	~R 88 077 indirect	—
Erlotinib and Bevacizumab Variant #01	—	R 26 036	28d	~16.4 mo	~49.1 mo	~52	~R 1 353 852 PFS proxy · indirect	7
Gemcitabine and Mitomycin Variant #01	—	R 8 504	28d	—	—	~2	~R 17 008 indirect	—
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	~11.1 mo	~6	~R 23 595 PFS proxy · indirect	8
FULV and Gemcitabine Variant #02	—	R 3 787	21d	—	—	~2	~R 7 575 indirect	—
FULV Variant #29	—	R 3 601	14d	~5.6 mo	~13.1 mo	~2	~R 7 201 PFS proxy · indirect	15
Gemcitabine and S-1 Variant #01 Partial	—	R 3 344	21d	—	~26.1 mo	~2	~R 6 688 PFS proxy · indirect	2
GemOx Variant #01	—	R 2 937	14d	~5.0 mo	~9.0 mo	~7	~R 20 560 PFS proxy · indirect	5
FELV Variant #01	—	R 2 934	21d	—	~12.0 mo	~2	~R 5 867 PFS proxy · indirect	—
Capecitabine and Mitomycin Variant #01	—	R 2 854	28d	—	—	~2	~R 5 708 indirect	—
Gemcitabine, Cisplatin, S-1 Variant #01 Partial	—	R 1 819	14d	—	~13.5 mo	~2	~R 3 638 PFS proxy · indirect	1
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~4.7 mo	~6.8 mo	~7	~R 11 705 PFS proxy · indirect	31
Capecitabine monotherapy Variant #01	—	R 1 039	21d	~5.7 mo	~7.5 mo	~8	~R 8 309 PFS proxy · indirect	11
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~1.8 mo	~10.9 mo	~2	—	6
Pemigatinib monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—

16 of 16 regimens shown